Evolving Adjuvant Treatments for HER2+ Early Breast Cancer - Episode 3
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Related Content: